Christopher Ryan Sullivan's most recent trade in Avalo Therapeutics Inc was a trade of 24,200 Restricted Stock Units done . Disclosure was reported to the exchange on March 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 48,400 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 24,206 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 7,285 | 16,921 | - | 8.5 | 61,631 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 163,000 | 163,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 186,700 | 186,700 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 72,600 | 72,600 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 511 | 1,262 | - | 3.4 | 1,748 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Accounting Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 955 | 9,004 | - | 1.6 | 1,499 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Interim CFO | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Dec 2020 | 5,095 | 8,049 | - | 2.3 | 11,606 | Common Stock |